Detalles de la búsqueda
1.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446802
2.
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Am J Hematol
; 89(11): E206-11, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25059397
3.
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.
Hemasphere
; 4(3): e380, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32647799
4.
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
J Cancer Res Clin Oncol
; 144(1): 187-188, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29063181
5.
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
J Cancer Res Clin Oncol
; 143(10): 2059-2066, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28551768
6.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Blood Cancer J
; 11(2): 16, 2021 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563899
Resultados
1 -
6
de 6
1
Próxima >
>>